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Chlorpyrifos was selected for EPA’s Endocrine Disruptor Screening Program (EDSP) based on widespread
use and potential for human and environmental exposures. The purpose of the program is to screen
chemicals for their potential to interact with the estrogen, androgen, or thyroid pathways. A battery of
11 assays was completed for chlorpyrifos in accordance with test guidelines developed for EDSP Tier 1
screening. To determine potential endocrine activity, a weight-of-evidence (WoE) evaluation was com-
pleted for chlorpyrifos, which included the integration of EDSP assay results with data from regulatory
guideline studies and the published literature. This WoE approach was based on the OECD conceptual
framework for testing and assessment of potential endocrine-disrupting chemicals and consisted of a sys-
tematic evaluation of data, progressing from simple to complex across multiple levels of biological orga-
nization. The conclusion of the WoE evaluation is that chlorpyrifos demonstrates no potential to interact
with the estrogen, androgen, or thyroid pathways at doses below the dose levels that inhibit cholinester-
ase. Therefore, regulatory exposure limits for chlorpyrifos, which are based on cholinesterase inhibition,
are sufﬁcient to protect against potential endocrine alterations. Based on the results of this WoE evalu-
ation, there is no scientiﬁc justiﬁcation for pursuing additional endocrine testing for chlorpyrifos.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
The term ‘‘endocrine disruptor’’ or ‘‘endocrine disrupting chem-
ical’’ was put forward in recent years by members of the scientiﬁc
community based on the hypothesis that certain substances may
have intrinsic properties allowing interaction with and potential
‘‘disruption’’ of the normal function of the endocrine system. Sub-
sequently, various efforts have been undertaken to ascribe an
unambiguous deﬁnition to the designation ‘‘endocrine disruptor’’.
One widely accepted deﬁnition agreed at the 1996Weybridge Con-
ference (now termed the Weybridge-deﬁnition) describes an endo-
crine disruptor as ‘‘an exogenous substance that causes adverse
health effects in an intact organism, or its progeny, secondary to
changes in endocrine function’’.
To address concerns that environmental chemicals could act as
endocrine disruptors and cause adverse health effects, provisions
were included in the 1996 Food Quality Protection Act as well as
amendments to Safe Drinking Water Act, both of which called for
the US EPA to screen chemicals, including pesticides, for potential
endocrine disrupting properties. In order to comply with these pro-visions, EPA initiated efforts in the mid-to-late 1990s to develop a
screening program designed to identify potential endocrine-dis-
rupting chemicals. Termed the Endocrine Disruptor Screening Pro-
gram (EDSP), this EPA effort was developed as a two-tiered
screening and testing program. The stated purpose of Tier 1 screen-
ing, which includes 11 assays, is to ‘‘identify substances with the
potential to interact with the estrogen, androgen, or thyroid hor-
mone systems’’. Tier 2 is designed to determine: (1) ‘‘whether a
substance may cause endocrine-mediated effects through or
involving estrogen, androgen, or thyroid hormone systems’’; (2)
‘‘the consequences to the organism of the activities observed in
Tier 1’’; and (3) ‘‘the relationship between doses of an endocrine-
active substance administered in the test and the effects observed’’
(US EPA, 2005). Five tests have been proposed for Tier 2 EDSP.
In 2007, EPA released a draft initial list of 73 chemicals for
screening which included primarily pesticide active ingredients
with a small number of HPV/pesticide ‘‘inert’’ chemicals (US EPA,
2007a). One chemical included on the initial EDSP screening list
was chlorpyrifos (O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl)ester
phosphorothioic acid), a widely-used organophosphate pesticide
product. As with other compounds on priority list 1 for endocrine
screening, chlorpyrifos’ selection was not due to effects, but was
based on criteria for potential for exposure through diet (food
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surfaces (US EPA, 2002; 2007a). The exposure potential was based
on EPA review of existing databases and those chemicals with po-
tential for exposure throughmultiple pathways were considered to
have a higher priority for inclusion on EDSP list 1. Of note, in June
2000, chlorpyrifos was voluntarily withdrawn from residential
uses in the US, thereby reducing residential exposures (US EPA,
2011a).
Chlorpyrifos is a pesticide product widely used in the US and
other countries to manage insect pests on many agricultural crops
including tree fruits and nuts, vines, vegetables, corn and soybeans.
It is a member of the organophosphate class of insecticides and
was ﬁrst introduced for use in the US in 1965. Since that time, it
has become one of the most widely studied pesticides from both
human health and environmental perspectives.
In 2009, a testing consortium was developed to respond to the
Tier 1 EDSP test orders for chlorpyrifos. In accordance with the EPA
EDSP, the consortium opted to submit existing data (i.e., other sci-
entiﬁcally relevant information (OSRI)) to fulﬁll a subset of the
EDSP assay requirements. However, based on somemethodological
differences and a desire to have a complete EDSP Tier 1 data set, it
was subsequently agreed to conduct all 11 Tier 1 assays. The Tier 1
battery for chlorpyrifos was completed and submitted to EPA in
2011 in accordance with the test order 24-month response period.
To determine the potential for endocrine activity, a weight-of-
evidence (WoE) evaluation was completed which included the
integration of EDSP assay results with existing data from regula-
tory guideline studies and the published literature. In order to pro-
duce the WoE evaluation of the chlorpyrifos EDSP data-set, several
existing WoE frameworks and methodologies were ﬁrst evaluated
(Borgert et al., 2011; Boobis et al., 2008; Rhomberg, 2010; Weed,
2005) for their potential utility in conducting this evaluation.
While some common features from these approaches were
adopted (e.g., reliance on a hypothesis-based approach, the need
to appropriately organize and integrate information, the need for
critical evaluation of data relevance and reliability), it was deter-
mined that the overall clarity and reliability of the evaluation
would be beneﬁted by utilizing an endocrine-speciﬁc approach to
the degree possible. While the Borgert et al. approach is speciﬁc
to the issue of endocrine disruption and EDSP, it was determined
at the time of the chlorpyrifos evaluation to not be sufﬁciently
developed for the purposes of producing a clear and straightfor-
ward WoE document. Thus, based on the currently availability of
methodologies, it was determined that a qualitative endocrine-
speciﬁc WoE evaluation approach would be utilized.
One common feature of all the approaches was the need to ﬁrst
organize all relevant information in a meaningful manner. To
accomplish this requirement, it was decided to base the WoE eval-
uation on the approach adopted under the OECD conceptual frame-
work for testing and assessment of potential endocrine-disrupting
chemicals. The conceptual framework represents the consensus
agreement of the OECD endocrine task force and thus can be con-
sidered as a well vetted and established approach. One purpose of
the framework is to facilitate the organization of data across multi-
ple levels of biological complexity in a straightforward manner
(OECD, 2010). This feature was important for the EDSP data-set gi-
ven the different test systems used (in vitro vs in vivo) and the need
to put this information into the appropriate context. Since the
framework was developed speciﬁcally for addressing the topic of
endocrine disruption, the test systems and approaches utilized
for EDSP are included speciﬁcally in the framework and thus can
easily be incorporated into the appropriate level for the WoE
evaluation. Speciﬁcally, the framework consists of ﬁve levels of
information including: (1) non-test information (e.g., physical–
chemical properties); (2) in vitro assay results; (3) in vivo assays
that inform on endocrine pathways; (4) in vivo apical assays thatevaluate speciﬁc endocrine endpoints; and (5) in vivo assays that
provide comprehensive data on potential adverse effects over mul-
tiple life stages of an organism. Thus, in general data obtained in
higher-tier test systems would carry more weight than those from
lower tiers. This approach is similar to that recommended by the
European Centre for Toxicology and Ecotoxicology of Chemicals
(ECETOC) in which higher-tier (i.e., in vivo apical) studies are more
important than lower- tier (i.e., in vitro or single endpoint in vivo)
studies in determining whether a chemical has endocrine disrupt-
ing properties (Bars et al., 2011).
In addition to the newly developed data under this Tier 1
screening, an extensive review was undertaken of published scien-
tiﬁc literature and multiple studies conducted under good labora-
tory practices (GLP) for pesticide registration purposes, both of
which span a host of endpoints that inform on endocrine disrup-
tion potential. Where relevant and reliable data was identiﬁed, this
information was also incorporated into the appropriate level of the
framework and ultimately included in the WoE evaluation.
The purpose of this manuscript is to summarize the results of
the Tier 1 EDSP results for chlorpyrifos and provide a WoE-based
conclusion, based on the approach used in this particular assess-
ment, on the potential for chlorpyrifos to interact with the estro-
gen, androgen or thyroid pathways. A WoE approach is
important, because the Tier 1 battery was designed to include
highly sensitive assays in order to minimize ‘‘false negative’’ re-
sults, which increases the likelihood of ‘‘false positive’’ ﬁndings
(EDSTAC, 1998). Consequently, undue weight should not be placed
on any single result. Isolated positive ﬁndings need to be inter-
preted carefully with the overall pattern of effects across the bat-
tery being the key ﬁnding, allowing ﬁrm conclusions on potential
endocrine activity.2. Methods
2.1. Tier 1 EDSP assays
EDSP Tier 1 assays were conducted in accordance with the iden-
tiﬁed test guidelines and are brieﬂy described in Table 1.2.2. Weight of evidence (WoE)
While there are many variations on conducting a WoE evalua-
tion (e.g., Borgert et al., 2011; Boobis et al., 2008; Rhomberg,
2010; Weed, 2005), there are several concepts in common between
the various approaches including: (1) gathering and organizing all
relevant information; (2) determining quality and reliability of
data; (3) integrating data from different sources in a manner that
facilitates evaluation and comparison of data from different
sources; (4) evaluating data for factors such as consistency, coher-
ence, adequacy, plausiblity, etc.; and (5) employing a weighting or
hypothesis-based evaluation system to draw conclusions on the
existing dataset (Borgert et al., 2011; Boobis et al., 2008; Rhom-
berg, 2010; Weed, 2005).
In order to produce a transparent and scientiﬁcally valid endo-
crine WoE evaluation for chlorpyrifos, existing approaches were
utilized to determine the reliability of information and ascribe
appropriate weight to the evidence. The general approach adhered
to was as follows: (1) gather all available information including
EDSP data, pesticide registration studies, and literature search re-
sults relevant to determining the potential for chlorpyrifos to inter-
act with the estrogen, androgen or thyroid pathways; (2)
Determine reliability of literature using Toxicological data Reliabil-
ity Assessment Tool (ToxRTool) (US EPA, 2011b); (3) Organize rel-
evant and reliable evidence according the 5-level OECD conceptual
framework for the Testing and Assessment of Endocrine Disrupting
Table 1
Brief description of Tier 1 EDSP screening assays.
Assay Test guidelinea Test system Exposure Endpoint summary
In vitro
ER binding OCSPPb 890.1250 Rat uterine cytosol ERs 16–20 h Displacement of radiolabeled 17b-estradiol to show interaction at
ERa
ER transactivation OCSPP 890.1300;
OECD 455
hERa-HeLa-9903 stably
transfected cell line
20–24 h Increased reporter gene activation (luciferase
chemiluminescence) achievingP10% of positive control response
(1 nM estradiol) indicates ERa agonism
AR binding OCSPP 890.1150 Rat ventral prostate cytosol ARs 20 h Displacement of radiolabeled R-1881 to show interaction at AR
Steroidogenesis OCSPP 890.1550;
OECD 456
H295R human adrenocortical
carcinoma cell line
48 h Increase or decrease in production of testosterone and/or estradiol
in the culture medium
Aromatase OCSPP 890.1200 Recombinant human aromatase 15 min Incubate 3H-androstenedione and aromatase; decreased
production of 3H-H2O indicates aromatase inhibition
In vivo
Uterotrophic OCSPP 890.1600;
OECD 440
Immature female CD rats PND 18–21 (oral
gavage)
Increased uterine weight indicates ER agonism
Hershberger OCSPP 890.1400;
OECD 441
Castrated male CD rats PND 55–64 (oral
gavage)
Increased or decreased accessory sex tissue weights indicates AR
agonism, AR antagonism or 5a-reductase inhibition
Female pubertal OCSPP 890.1450 Juvenile female CD rats PND 22–42 (oral
gavage)
Accelerated or delayed puberty onset, alterations in estrous cycle
(female), organ weight changes (reproductive, thyroid, and
accessory sex tissues), reproductive/thyroid histopathology, and
terminal hormone measurements (T4, TSH, testosterone in males
only) indicate alterations in the estrogen, androgen and/or thyroid
pathways
Male pubertal OCSPP 890.1500 Juvenile male CD rats PND 23–53 (oral
gavage)
Amphibian
metamorphosis
OCSPP 890.1100;
OECD 231
Xenopus laevis tadpoles 21 days (CF) Alterations in hind limb length, developmental stage, and/or
thyroid histopathology indicate alterations in the thyroid
pathway
Fish short-term
reproduction
OCSPP 890.1350;
OECD 229
Sexually mature fathead minnows 21 days (CF) Changes in fecundity, fertility, gonado-somatic index, tubercle
score, gonadal histopathology, and plasma vitellogenin
(testosterone, 17b-estradiol optional) indicate alteration in the
estrogen and/or androgen pathways
ER = estrogen receptor; AR = androgen receptor; T4 = thyroxine; TSH = thyroid stimulating hormone; NF = Nieuwkoop and Faber (see test guideline); CF = continuous ﬂow-
through test system.
a Test guidelines available at: http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series890.htm and http://www.oecd-ilibrary.org/environment/oecd-
guidelines-for-the-testing-of-chemicals-section-4-health-effects_20745788;jsessionid=3mx7t5besbs06.delta (accessed July 15, 2012).
b OCSPP; formerly OPPTS.
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bles addressing endocrine speciﬁc pathways (estrogen, androgen,
thyroid); and (5) evaluate existing relevant and reliable data for
consistency, coherence, and biological plausibility to identify pat-
terns of effects or discordant ﬁndings and summarize ﬁndings
and conclusions for each pathway. At the request of EPA, Tier 1 re-
sults for chlorpyrifos were evaluated in context with cholinester-
ase (ChE) inhibition, the acknowledged and accepted sensitive
toxicological endpoint used for regulatory purposes for organo-
phosphate chemicals such as chlorpyrifos.
The approach selected for conducting the chlorpyrifos endo-
crine WoE evaluation is described in greater detail below.2.2.1. Gather relevant data
The ﬁrst step in conducting this WoE evaluation for chlorpyrifos
was to gather all relevant information. Relevant information in-
cludes the eleven Tier 1 EDSP assays, relevant studies previously
conducted for the purpose of registration (e.g., 40 CFR Part 158
data requirements for pesticides) and/or product stewardship,
and some studies identiﬁed in the peer-reviewed literature. To
identify studies of potential relevance in the literature, a compre-
hensive search was conducted and the resulting list of studies
was then evaluated using the ToxRTool (see below) to determine
if chlorpyrifos has the potential to interact with the estrogen,
androgen or thyroid pathways in mammalian or wildlife systems.
The assays and endpoints employed by EDSP Tier 1 were also used
as a general guide for determining potential relevance of literature
publications, again focusing on those that provided insight on
estrogen, androgen, or thyroid pathways. Those determined to be
relevant were included in subsequent steps of the WoE evaluation
in a transparent manner. We would note that the eleven Tier 1 as-says were not evaluated using the ToxRTool as they represent the
results of a multi-year development and validation process and
collectively represent what is considered a sound initial battery
for endocrine evaluation. If evaluated in the ToxRTool, the ex-
pected scores for the EDSP Tier 1 screens would be ‘‘Category 1 –
reliable without restriction’’ in accordance with the requirements
of validated, good laboratory practices (GLP)-compliant guideline
studies. The ToxRTool examines quality of a test report, but does
not assess data relevance (appropriateness of an assay to identify
a hazard) or data adequacy (i.e., usefulness for risk assessment)
(Schneider et al., 2009).2.2.2. Determine data reliability
Studies employing internationally recognized guidelines (e.g.,
Table 3), particularly those that adhered to good laboratory prac-
tices (GLPs), were considered ‘‘reliable without restrictions’’ (Kli-
misch category 1) as is standard practice for assigning Klimisch
scores (Klimisch et al., 1997). Following identiﬁcation of other
potentially relevant literature, a data quality evaluation was per-
formed on each publication. To ensure that this step adhered to a
standardized and well-documented process, a publicly-available
data quality evaluation tool was utilized. This tool is called the
‘‘ToxRTool’’ (Toxicological data Reliability Assessment Tool) and
is published and also available to the public on the European Cen-
tre for the Validation of Alternative Methods (ECVAM) website
(Schneider et al., 2009). The purpose of the tool is to provide a
transparent and harmonized method for evaluation of data quality
for in vivo and in vitro toxicology studies. Speciﬁcally, the ToxRTool
is a spreadsheet that prompts the reviewer to respond to a number
of questions important to data quality and reliability. Questions in-
cluded are related to factors such as: adequate identiﬁcation of the
Table 2
Organization of endocrine relevant data according to OECD conceptual framework.
OECD
level
General information EDSP Tier 1 speciﬁc information Data potentially available from pesticide registration
studies
Level 1  Physical chemical properties
 Prioritization information
 QSAR (related chemicals)
Level 2 In vitro assays  Estrogen or androgen receptor binding (OPPTS 890.1250)
 Estrogen receptor transcriptional activation assay (OPPTS
890.1300)
 Steroidogenesis (OPPTS 890.1550)
 Aromatase (OPPTS 890.1200)
Level 3 In vivo assays that provide data
about
endocrine pathways
 Uterotrophic (OPPTS 890.1600)
 Hershberger (OPPTS 890.1400)
 Amphibian metamorphosis (OPPTS 890.1100)
Level 4 In vivo assays providing data on
adverse effects on ED endpoints
 Male and female pubertals (OPPTS 890.1450; OPPTS
890.1500)
 Fish short-term reproduction (OPPTS 890.1350)
 Repeated dose 28-day or 90-day (OECD 407, 408)
 One-generation reproduction assay
 Prenatal developmental toxicity
 Chronic toxicity and carcinogenicity
 Reproduction screening test (enhanced OECD 421/
OECD 422)
 Developmental neurotoxicity
 Multigeneration study following older test guidelines
Level 5 In vivo assays providing more
comprehensive data on adverse
effects over more parts of the
life cycle of an organism
 EDSP Tier 2 studies  Extended one-generation reproductive toxicity study
 Two-generation reproduction (following updated
test guideline)
 Life cycle or multigeneration studies in various
species
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system, appropriate study design, documentation of results, and
plausibility. Based upon the responses to each individual question,
the tool then assigns an overall score which is essentially a Kli-
misch category of 1 (reliable without restrictions), 2 (reliable with
restrictions), or 3 (not reliable) (Klimisch et al., 1997). Conducting a
data quality evaluation is consistent with EPA’s WoE approach and
the ToxRTool is cited as one possible approach in EPA’s WoE guid-
ance document (US EPA, 2011b).
2.2.3. Organize relevant and reliable data according to OECD
conceptual framework
Data considered to be of sufﬁcient reliability for inclusion in the
WoE evaluation were those that received Klimisch scores of 1 or 2.
These data were then organized according to the OECD conceptual
framework for testing and assessment of endocrine disrupting
chemicals (OECD, 2010). The 5-level conceptual framework (Ta-
ble 2), while not intended to be a testing program like EDSP, is a
valuable tool for use in organizing or grouping existing data into
different levels of complexity. It is a logical and scientiﬁcally devel-
oped approach that can be used to assist in evaluating an existing
data set for evidence of effects on the endocrine system. Generi-
cally, the conceptual framework consists of ﬁve levels with level
1 corresponding to the lowest level of complexity and level 5 data
being the most biologically complex (i.e., apical studies) (OECD,
2010).
Thus, EDSP Tier 1 assays correspond to levels 2–4 of the concep-
tual framework while Tier 2 tests would be equivalent to level 5.
Existing data generated for pesticide registration could correspond
to one or more of the levels, but will most typically be considered
level 4 or level 5 information depending upon the study design and
speciﬁc guideline followed. Inclusion of guideline studies (e.g.,
those used for pesticide registration) in the WoE evaluation is con-
sistent with the requirements of the program and EPA practices
(i.e., OSRI). Accordingly, EPA stated that:
‘‘. . . Part 158 test guideline studies and OECD equivalents may pro-
vide relevant scientiﬁc and technical information to be considered
along with the results of Tier 1 screening in a WoE analysis todetermine whether or not a chemical has the potential to interact
directly or indirectly with the E (estrogen), A (androgen), or T (thy-
roid) hormonal pathways (US EPA, 2011b).’’
By organizing all available relevant data according to the con-
ceptual framework, the process of conducting a WoE evaluation
is facilitated. Consistent ﬁndings across levels can be identiﬁed
and aid in the generation of mode-of-action hypotheses. In cases
where data are not in agreement across levels, information corre-
sponding to a higher level of biological complexity or organization
would typically receive higher weighting than that of a lower level
due to the greater biological relevance of the higher level studies
(e.g., inclusion of metabolism, compensatory in vivo mechanisms,
etc.). This approach is consistent with EPA’s WoE methodology
and fulﬁlls the objective of providing a ‘‘structured and transparent
approach to facilitate the WoE determination’’ (US EPA, 2011b).
Thus, in this WoE evaluation, EDSP Tier 1 data and high quality
relevant data from other sources are grouped according to the
ﬁve-level OECD conceptual framework and subsequently weighted
according to the grouping.
2.2.4. Organize information according to endocrine speciﬁc pathways
Following grouping of data of sufﬁcient relevance and quality,
the available information was then organized in a manner to facil-
itate identiﬁcation of potential effects on each of the three main
pathways addressed by EDSP Tier 1. With an emphasis on Tier 1 re-
sults, studies with relevance for identifying potential interactions
with the estrogen pathway were summarized in a single table
and the same approach was then taken with the androgen and thy-
roid pathways. Determination of relevant endpoints (Table 3) was
based upon review of standard guideline studies which incorporate
designs and include biological parameters which inform on endo-
crine systems. To facilitate identiﬁcation of any potential patterns
indicative of an interaction, results for each assay were summa-
rized and an overall WoE narrative was provided for each pathway
based upon the integration of the available information. Where re-
sults were not fully concordant across all data sources, further dis-
cussion was provided for several key parameters with nature and
magnitude of the effect, dose-level at which the effect occurred,
Table 3
Endpoints relevant to evaluation of endocrine system interaction.
Type of study Endpoints included in study design
Subchronic Growth, ovarian weight, liver weight, kidney weight, adrenal weight, testes weight, clinical chemistry, and histopathology of the
following organs and/or systems – uterus, ovary, thyroid, kidney, adrenal, pituitary, liver, oviduct, parathyroid, epididymides, testis,
prostate, and seminal vesicle
Chronic toxicity/
carcinogenicity
Growth, ovarian weight, thyroid weight, liver weight, kidney weight, adrenal weight, testes weight, clinical chemistry, and
histopathology of the following organs and/or systems – uterus, ovary, thyroid, kidney, adrenal, pituitary, liver, epididymides, testis,
prostate, seminal vesicle, and preputial gland
Developmental toxicity Growth, uterine weight, liver weight, pup malformations
Reproductive toxicity Females: growth, time to mating, clinical chemistry and histopathology of the following organs and/or systems – uterus, ovary, thyroid,
kidney, adrenal, pituitary, liver, and oviduct; Males: histopathological evaluation of the following organs and/or systems – epididymides,
testes, thyroid, kidney, adrenal, pituitary, prostate, liver, and seminal vesicle
⁄It should be noted that these endpoints were examined in animals exposed during critical developmental stages including prenatal,
early postnatal, and the peripubescent period into adulthood
Developmental
neurotoxicity study
Growth, age at preputial separation
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forming overall conclusions for each pathway. Further, the data
for each pathway were evaluated for consistency, coherence, and
biological plausibility with consideration of strengths and limita-
tions for each assay or data type. All of these are key considerations
discussed in EPA’s September, 2011 guidance document on con-
ducting WoE evaluations for EDSP) (US EPA, 2011b). In accordance
with the request from the EPA Endocrine Disruptor Review Team
(EDRT) and as described in the response to the chlorpyrifos OSRI
submission, evaluation of ChE inhibition was included in most of
the in vivo EDSP Tier 1 assays (one exception: the uterotrophic as-
say for which the ChE inhibition could be reasonably predicted
based on previous toxicity data). Dose levels for mammalian assays
were selected based upon existing or range-ﬁnding data to obtain
signiﬁcant brain ChE inhibition at the highest dose without causing
overt neurotoxicity (although the high dose for the uterotrophic
assay was based on decreased body weight gain). This approach
is consistent with the regulation of chlorpyrifos by EPA and other
regulatory agencies where ChE inhibition is recognized as being
the most sensitive, primary toxicological response; red blood cell
(RBC) ChE inhibition, which is more sensitive than brain ChE, is
the endpoint upon which risk assessments are based (US EPA,
2011a). Thus, protection against the sensitive effect of RBC ChE
inhibition will also protect against effects that could occur at high-
er exposure levels. For non-mammalian assays, high test concen-
trations of chlorpyrifos were selected based on the maximum
tolerated concentration (MTC), which is deﬁned as the highest test
concentration of the chemical which results in less than 10% acute
mortality. The MTC can also be estimated as 1/3 of the acute LC50.
In order to accurately estimate the MTC for the non-mammalian
assays, 14-day range-ﬁnding exposure studies with the species of
interest (i.e., Pimephales promelas and Xenopus laevis) were con-
ducted prior to the deﬁnitive assays.
2.2.5. Drawing conclusions on Tier 1
Finally, following the development of the WoE summary and
consideration of any patterns of ﬁndings, conclusions were pro-
vided for each of the three endocrine pathways. In addition, a
determination on the need for potential follow-up work, including
EDSP Tier 2 testing, was provided.
3. Results
3.1. Level 1
Level 1 information includes information available on a chemi-
cal prior to conducting new screening or testing that can inform on
the potential to interact with the endocrine system. Thus, informa-tion such as QSAR, physical chemical properties, and other existing
information can be included within Level 1. Also important would
be criteria or information that might be included within a determi-
nation of prioritization for next level screening or testing. A sum-
mary of relevant available Level 1 information for chlorpyrifos
follows.
3.1.1. Physical–chemical properties
Chlorpyrifos is an off-white, low melting point, crystalline solid
at room temperature with a mercaptan-like odor. It has a moderate
vapor pressure (2.2  105 mm Hg) and shows a low tendency to
volatilize from water (Henry’s air–water partition constant
6.7  106 atm m3/mol). It is of low solubility in water (1.4 mg/L)
but highly soluble in a range of organic solvents. It is moderately
unstable in aqueous media with an increasing hydrolytic degrada-
tion rate at higher values of pH. The octanol/water partition coefﬁ-
cient (log Kow = 4.7) and the measured bioconcentration factor of
2727 in ﬁsh indicates the potential for moderate bioconcentration
in aquatic organisms (US EPA, 2008).
3.1.2. Absorption, distribution, metabolism, excretion (ADME)
Absorption, distribution, metabolism and excretion studies
demonstrate that over 70% of orally administered chlorpyrifos is
absorbed (Eaton et al., 2008; Timchalk et al., 2002). Dermally
administered chlorpyrifos was well absorbed in mice (>60%) but
poorly absorbed in humans (<3%) (US EPA, 2011a). Once absorbed,
chlorpyrifos is rapidly metabolized and rapidly excreted (27 h half-
life in humans) primarily in the urine, as 3,5,6-trichloropyridinol
(TCP) and conjugates that hydrolyse to 3,5,6-TCP (Timchalk et al.,
2002; US EPA, 2011a). In ADME studies using radiolabeled test
material, concentrations of radioactivity in all tissues were low,
indicating that chlorpyrifos and its metabolites do not selectively
accumulate in any tissue. The disposition of chlorpyrifos was unaf-
fected by prior exposure and no signiﬁcant dose or sex-related dif-
ferences have been observed in the metabolism of chlorpyrifos
(Timchalk et al., 2002; US EPA, 2011a).
3.2. Level 2
Results of the 11 EDSP Tier 1 assays are summarized in Table 4.
3.2.1. In vitro estrogen receptor binding assay
At concentrations of chlorpyrifos ranging from 1010 to 103 M,
there were no appreciable alterations in 17b-estradiol ER binding
activity. Thus, the results of the in vitro estrogen receptor binding
assay using rat uterine cytosol indicate thatchlorpyrifos was nega-
tive (not interactive) for estrogen receptor binding at concentra-
tions up to 103 M.
Table 4
Summary of chlorpyrifos EDSP Tier 1 assay results.
Tier 1 assay Potential endocrine MoA
detected
Concentrations or dose
levels
Assay results Assay LOEL Comments
In vitro
ER binding E (AntiE) 1010–103 M  NA Not interactive at ER
ER transactivation assay E 1010–104 M + (weak) 105 and
104 M
10–25% induction (rel. to 1 nM E2)
AR binding A (AntiA) 1010–103 M +/
(equivocal)
104 and
103 M
Lower in vivo blood conc. causes marked
brain and RBC ChEI
Steroidogenesis T & E steroidogenesis 1010–104 M + 105 and
104 M
T increased and E2 decreased; lower
in vivo blood conc. causes marked brain
and RBC ChEI
Aromatase E steroidogenesis 1010–103 M  NA Non-inhibiting
In vivo
Uterotrophic E 0, 0.5, 1.5 or 4 mkd  NA 23% decrease in body wt. gains; 4 mkd
causes RBC ChEI
Hershberger A (AntiA); DHT
steroidogenesis
0, 1, 6 or 12 mkd  NA RBC ChEI at all dose levels, brain ChEI at 6
and 12 mkd
Female pubertal E (AntiE); E steroidogenesis;
HPG axis; HPT axis
0, 0.5, 1 or 2 mkd  NA RBC ChEI at all dose levels, brain ChEI at
2 mkd
Male pubertal A (AntiA); T
steroidogenesis; HPG axis;
HPT axis
0, 0.5, 1 or 2 mkd  NA RBC ChEI at all dose levels, brain ChEI at
2 mkd
Amphibian
metamorphosis
HPT axis 0, 0.215, 0.881, 3.68, or
13.6 lg/L
 NA Limb and tail ChEI at 3.68 and 13.6 lg/L;
no thyroid histopathology at any dose
level
Fish short-term
reproduction
E (AntiE); A (AntiA); T & E
steroidogenesis; HPG axis
0, 0.251, 0.812, or 3.02 lg/L + (with ChEI) NA Brain ChEI at all doses in females and
0.812 and 3.02 lg/L in males
E = estrogenicity; A = androgenicity; T = testosterone; E = estradiol; DHT = dihydrotestosterone; HPG = hypothalamic-pituitary–gonadal; HPT = hypothalamic–pituitary–
thyroid; ChEI = cholinesterase inhibition; mkd = mg/kg body wt/day.
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At the two highest concentrations of chlorpyrifos (105 and
104 M), there was a reproducible, slight increase in estrogen
receptor-mediated transcriptional activity in stably transfected hu-
man hERa-HeLa-9903 cells, as determined by the guideline crite-
rion of at least 10% of the response of the positive control (1 nM
17b-estradiol). The maximum response (RPCmax) induced by chlor-
pyrifos in the ER transactivation assay ranged from 10.2% to 25.4%
of the response induced by the positive control. The results of the
in vitro estrogen receptor transcriptional activation assay indicate
that chlorpyrifos induced a weak increase in estrogen receptor-
mediated transactivation, but only at in vitro concentrations signif-
icantly higher than in vivo blood levels that markedly inhibit brain
and RBC ChE activity in adult female rats.3.2.3. In vitro androgen receptor binding assay
At concentrations of chlorpyrifos ranging from 1010 to 105 M,
there were no appreciable alterations in R1881 AR binding activity.
At the two highest concentrations of chlorpyrifos tested, including
the assay limit concentration (1 mM, 103 M), there was a decrease
in bound radioligand that was classiﬁed as an equivocal response
as described in the guideline. The results of the in vitro AR binding
assay using rat prostate cytosol indicate that chlorpyrifos was
equivocal for AR binding at in vitro concentrations (104 and
103 M), signiﬁcantly higher than in vivo blood levels that mark-
edly inhibit brain and RBC ChE activity in adult female rats.3.2.4. In vitro steroidogenesis assay
Chlorpyrifos was tested for effects on steroidogenesist at con-
centrations ranging from 1010 to 104 M. Hormone production
was reproducibly and statistically altered at the two highest con-
centrations tested (105 and 104 M). Speciﬁcally, testosterone
production was decreased and estradiol production was increased
compared to solvent controls. The results of the in vitro steroido-
genesis assay using the human adrenocortical carcinoma cell lineH295R with chlorpyrifos indicate that chlorpyrifos altered steroi-
dogenesis, but only at in vitro concentrations signiﬁcantly higher
than in vivo blood levels that markedly inhibit brain and RBC ChE
activity in adult female rats.3.2.5. In vitro aromatase assay
At concentrations ranging from 1010 to 103 M, chlorpyrifos
did not inhibit aromatase activity according to the decision criteria
of the aromatase assay guideline. Thus, the results of the human
recombinant aromatase assay with chlorpyrifos indicate that the
test material was classiﬁed as a non-inhibitor of aromatase
activity.3.2.6. Other scientiﬁc literature
Results of literature searches to identify both ecotoxicological
andmammalian toxicology studies of potential relevance to inform
on endocrine endpoints are included in Supplemental Tables S1
and S2. Based on the results of the literature search, nine published
Level 2 studies were identiﬁed and were determined to be of po-
tential relevance regarding mammalian toxicology (Supplemental
Table S1). Next, a reliability evaluation was conducted using the
ToxRTool on these nine published studies that utilized in vitro as-
says to assess the potential of chlorpyrifos to act on the endocrine
system. Among the nine studies, ﬁve studied effects on the estro-
gen receptor, three on the androgen receptor, two on aromatase
activity, one on thyroid hormone function, and one on gonadotro-
pin-releasing hormone. All the studies evaluated were considered
to belong to Reliability Category 3, or not reliable, and not to be
used as key studies, for not meeting certain evaluation criteria
speciﬁed in the ToxRTool. Studies were considered Category 3, as
they failed to meet the criteria of critical importance to achieve
Category 1 or 2. The common reasons for not meeting these critical
criteria were the following:
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tration range, LOEC or EC20 were shown);
 Only one concentration was tested, or data lacked concentration
response;
 Lack of cytotoxicity measurement or cytotoxicity data were not
shown;
 Lack of positive or negative/vehicle control.
Other common reasons for unmet criteria include the lack of
purity information, and insufﬁcient information on the test sys-
tems (e.g., passage number or metabolic competence of the cell
line used).
3.3. Level 3
3.3.1. Organophosphates and ChE inhibition
A relevant point pertaining to the use and interpretation of
EDSP data derived from Tier 1 screening assays is the relative sen-
sitivity of endocrine endpoints compared with the long-standing
mode/mechanism of action of organophosphate compounds,
which is inhibition of the enzyme acetylcholinesterase. As stated
by the US EPA’s Ofﬁce of Pesticide Programs (US EPA, 2000a), ‘‘In
a weight of the evidence assessment of cholinesterase-inhibiting
substances, acetylcholinesterase inhibition in the nervous system
is viewed as a key event in the mechanism of toxicity of these com-
pounds and an important critical effect to consider in the hazard
assessment’’.
The conclusion that inhibition of RBC ChE continues to be the
most sensitive marker of exposure, was recently reafﬁrmed by
the EPA in its preliminary health risk assessment for chlorpyrifos
(US EPA, 2011a). As quoted from that document:
‘‘The toxicology database for chlorpyrifos is substantially complete
(40 CFR 158.340 guideline studies have been submitted). . . In 2000,
the Agency concluded for chlorpyrifos that inhibition of cholinester-
ase (ChE) was the most sensitive effect in all of the animal species
evaluated (rats, mice, rabbits dogs) and in humans, regardless of
exposure duration. The Agency is maintaining at this time, based
on available data, that cholinesterase inhibition (ChEI) provides
the most sensitive dose response information for deriving points
of departure for chlorpyrifos. In animals, signiﬁcant inhibition of
plasma and red blood cell (RBC) ChE occur at doses below those
that cause brain ChE inhibition.’’Therefore, for this WoE evaluation, observations reported in
Tier 1 screening assays have been put within the context of ChE
inhibition using either concomitant measurements or the extrapo-
lation of ChE measurements from previous toxicity studies.
3.3.2. Uterotrophic assay
Chlorpyrifos dose levels used in the uterotrophic assay (6 rats/
group) were 0, 0.5, 1.5 and 4 mg/kg/day. There was no animal mor-
tality, treatment-related clinical signs, or treatment-related
changes in body weight. Body weight gains at 4 mg/kg/day for
the 4-day study period were decreased by 22.6% compared to the
vehicle control group, indicating that a maximum tolerated dose
was achieved. There were no treatment-related effects on uterine
weights in any chlorpyrifos-treated group compared to weights
of the vehicle group. The positive control group had the expected
uterine weight increases. Uterine weights of the vehicle-treated
animals met the performance criteria outlined in the applicable
test guidelines, indicating acceptable assay sensitivity. While ChE
inhibition was not directly assessed in this study, data from a pre-
vious study (Marty et al., 2012) demonstrated that 4 mg/kg/day
chlorpyrifos would have caused signiﬁcant RBC ChE inhibition after3 days of repeated dosing. Overall, there was no indication of estr-
ogenicity from chlorpyrifos at doses 64 mg/kg/day.
3.3.3. Hershberger assay
Chlorpyrifos dose levels used in the Hershberger assay (7 rats/
group) were 0, 1, 6 and 12 mg/kg/day. There were no treatment-
related clinical signs effects on body weight associated with chlor-
pyrifos treatment. Body weight gains were decreased by 610.8% in
chlorpyrifos-treated groups over the dosing period (TD 1–11). The
improvement in body weight gains was attributed to increases in
feed consumption in these animals. All study animals completed
preputial separation prior to necropsy. At necropsy, there were
no gross lesions attributed to treatment with chlorpyrifos. There
were signiﬁcant, treatment-related increases in absolute adrenal
weights at 6 and/or 12 mg/kg/day chlorpyrifos with and without
TP. Accessory sex tissue (AST) weights (i.e., ventral prostate, semi-
nal vesicles, levator ani-bulbocavernosus muscles, Cowper’s
glands, and glans penis) were not signiﬁcantly altered at any dose
of chlorpyrifos in the androgenic portion of the assay. In the
antiandrogenic portion of the assay, there was a small, but signif-
icant, decrease in glans penis weights at P6 mg/kg/day chlorpyri-
fos with TP; however, there were no signiﬁcant decreases in any
other AST weights at 612 mg/kg/day chlorpyrifos. According to
the test guidelines (OECD 441; OCSPP 890.1400), a statistically sig-
niﬁcant decrease in two or more AST weights is required to deem a
test substance ‘‘positive’’ for antiandrogenicity. The positive (TP)
and negative (TP with ﬂutamide) control compounds produced
the expected responses. The assay met the CV performance criteria
outlined in the corresponding test guidelines, indicating the assay
had appropriate sensitivity. Based on the lack of statistically signif-
icant, treatment-related changes in two AST organ weights, chlor-
pyrifos at doses 612 mg/kg/day was deemed negative for both
androgenic and antiandrogenic activity in the Hershberger assay.
ChE activity, which was signiﬁcantly inhibited in RBCs at all dose
levels (LOEL = 1 mg/kg/day) and in brain at P6 mg/kg/day chlor-
pyrifos, remains a highly sensitive endpoint to detect chlorpyrifos
exposure and toxicity.
3.3.4. Amphibian metamorphosis assay (AMA)
In the AMA, there were no signiﬁcant effects on tadpole survival
or behavior at 613.6 lg/L chlorpyrifos. At day 7, there was a signif-
icant reduction in tadpole snout-vent length in the 13.6 lg/L chlor-
pyrifos treatment. On day 21, snout-vent length and weight were
signiﬁcantly reduced in the 3.68 lg/L treatment, and snout-vent
length, wet weight, developmental stage and normalized hind limb
length were all signiﬁcantly reduced in the 13.6 lg/L treatment
compared to controls. Additionally at day 21, tadpoles exposed to
either 3.68 or 13.6 lg/L chlorpyrifos had signiﬁcantly reduced
ChE activity in both the tail and hind limb tissues compared to con-
trols, but there were not associated histopathological ﬁndings.
There were no treatment-related histopathological effects ob-
served in the thyroid glands from chlorpyrifos-exposed tadpoles.
There were no signs of advanced development (as measured by in-
creased developmental stage and hind limb length) or asynchro-
nous development among chlorpyrifos-exposed tadpoles on
either day 7 or day 21 of the exposure. Since there were no signs
of advanced development and no treatment-related histopatholo-
gical effects in the thyroid glands, chlorpyrifos is considered ‘‘likely
thyroid inactive’’ in the amphibian metamorphosis assay.
3.3.5. Other scientiﬁc literature
In a similar manner to level 2 studies, the ToxRTool was utilized
to assess the reliability of mammalian toxicological data consid-
ered to be consistent with OECD level 3. This evaluation was con-
ducted on a total of seven published studies from 1993 to 2010
that utilized in vivo models to assess the potential activity of
256 D.R. Juberg et al. / Regulatory Toxicology and Pharmacology 66 (2013) 249–263chlorpyrifos on the endocrine system (Supplemental Table S1).
Among the seven studies, two were epidemiological studies that
were conducted on human subjects. These studies were considered
not relevant in the context of this evaluation, as no meaningful
comparison and correlation could be established between these
studies and the in vivo mammalian studies, including in the EDSP
Tier 1 assays. Of the ﬁve remaining studies in animal models, three
focused on thyroid hormones, one focused on sex hormones, and
one assessed a variety of metabolic and reproductive hormones.
None of these studies has a similar study design to the EDSP Tier
1 in vivomammalian assays. All the studies were considered to be-
long to Reliability Category 3, or not reliable, and not to be used as
key studies. The common reasons for not meeting these critical cri-
teria are the following:
 Route of administration lacks relevance.
 Only one dose was tested, or data lacked dose response.
 Lack of evaluation of toxicities in other organ systems or end-
points (e.g., liver, body weight) to determine whether the endo-
crine effects were primary or secondary to general toxicities.
 Lack of or questionable statistical analysis.
Other common reasons for unmet criteria included the lack of
purity or source information for chlorpyrifos, lack of body weight
information for the animals used, and insufﬁcient information on
animal housing conditions for repeat dose studies, etc.
One study by Sparling and Fellers (2009) (Supplemental
Table S2) was found by ToxRTool analysis system to be ‘‘Category
1 – Reliable without restrictions’’. Two species of amphibians
indigenous to California, USA, Pseudacris regilla and Rana boylii,
were exposed in the laboratory to a series of chlorpyrifos concen-
trations (0.8–200 lg/L) from the free-swimming stage (Gosner
stage 25) through to completion of metamorphosis. Control sur-
vival was acceptable (80–93%). Sparling and Fellers (2009) re-
ported that chlorpyrifos affected the body weight and length of
tadpoles, and that the reduction in growth of tadpoles led to a de-
lay in time to metamorphosis for P. regilla and smaller body sizes at
metamorphosis for R. boylii. These observations were correlated
with signiﬁcant inhibition of cholinesterase activity (650%).
According to the decision scheme of the OECD 231 amphibian
metamorphosis assay, delay in metamorphosis per se is not indic-
ative of a speciﬁc interaction with the thyroid hormone pathway
because generalized stress can cause delays in metamorphosis
independent of any direct effect on thyroid hormone signaling.
The pattern of response reported by Sparling and Fellers is similar
to that observed in the EDSP Tier 1 amphibian metamorphosis as-
say reported by Coady et al. (2011) (i.e., reduced growth, cholines-
terase inhibition, delayed metamorphosis, but no thyroid
histopathology). Therefore, the ﬁndings of Sparling and Fellers
(2009) extend the conclusion reported by Coady et al. (2011) that
chlorpyrifos ‘‘is likely thyroid inactive’’ not only in X. laevis, but also
in two other amphibian species, P. regilla and R. boylii.
3.4. Level 4
3.4.1. Male and female pubertal assays
Chlorpyrifos dose levels used in the male and female pubertal
assays (16 rats/sex/dose) were 0, 0.5, 1 or 2 mg/kg/day. There
was no treatment-related mortality or clinical signs, and body
weights/body weight gains were not altered at any dose of chlor-
pyrifos in either the male or female pubertal assays. Mean ages
and body weights at vaginal opening and preputial separation
were similar between treated animals and controls with respective
values ranging from PND 34.3–35.3 and 109.9–115.9 g in chlor-
pyrifos-treated females to PND 35.4 and 115.8 g in the control fe-
males for vaginal opening and PND 43.8–44.2 and 200.0–204.4 gin chlorpyrifos-treated males to PND 43.8 and 199.0 g in the con-
trol males. In estrous cycle assessments, there were no signiﬁcant
treatment-related effects on mean estrous cycle length, age at ﬁrst
estrus, percent cycling and percent regularly cycling females. There
were no effects on mean serum levels of T4 or TSH levels at any
dose in either sex and no effect on serum testosterone levels in
males. In both males and females, there were signiﬁcant treat-
ment-related decreases in RBC ChE activity at each dose level;
RBC ChE was inhibited by 19–34%, 86–88% and >99% at 0.5, 1.0
and 2.0 mg/kg/day chlorpyrifos, respectively. At 2.0 mg/kg/day
chlorpyrifos, brain ChE activity was signiﬁcantly inhibited (22%
and 23% in females and males, respectively). The RBC and brain
ChE inhibition indicated that the animals were sufﬁciently chal-
lenged with the high dose of chlorpyrifos. There were no gross
ﬁndings at necropsy and no histopathological lesions in the repro-
ductive organs (uterus, ovaries, testis, epididymis), kidneys or thy-
roid with chlorpyrifos treatment. Generally, results from these
studies were within acceptable ranges for mean and CV perfor-
mance criteria as speciﬁed for control animals in the test guideline.
Thus, the pubertal female andmale assays had sufﬁcient sensitivity
to detect endocrine-mediated changes if these changes were
present.
Based on the lack of treatment-related changes in puberty on-
set, estrous cycle, endocrine-sensitive organ weights, serum T4,
TSH or testosterone levels, and uterine, ovarian, testicular, epidid-
ymal and thyroid histopathology, there was no evidence of endo-
crine activity for chlorpyrifos in the male or female pubertal
assays at doses up to and including 2.0 mg/kg/day, the highest dose
level tested. ChE activity, which was signiﬁcantly inhibited in RBCs
at all dose levels and in brain at 2.0 mg/kg/day chlorpyrifos, re-
mains a highly sensitive endpoint to detect chlorpyrifos exposure
and toxicity.3.4.2. Fish short-term reproduction assay (FSTRA)
There were no signiﬁcant effects on fathead minnow survival or
behavior in response to concentrations of chlorpyrifos ranging
from 0.251 to 3.02 lg/L. After 21 days of exposure, there were no
statistically signiﬁcant changes in chlorpyrifos-exposed ﬁsh for
the following endpoints: wet weight, length, gonado-somatic
index, tubercle score, and plasma concentrations of VTG,
17b-estradiol and testosterone. Furthermore, there were no treat-
ment-related histopathological effects in the ovaries and testes in
response to chlorpyrifos exposure. However, a statistically signiﬁ-
cant decrease in fecundity was noted among ﬁsh in all treatment
levels of chlorpyrifos (0.251, 0.812, and 3.02 lg/L) at test termina-
tion. In addition, female brain ChE was signiﬁcantly reduced in a
dose-dependent manner at all tested concentrations of chlorpyri-
fos and male brain ChE was signiﬁcantly reduced in both the
0.812 and 3.02 lg/L treatment groups. Brain was deemed the most
relevant tissue to measure ChE activity since the central nervous
system plays a key role in behavior and activity coordination;
blood cholinesterase was not measured. These data indicate that
ChE inhibition is a more sensitive marker to chlorpyrifos exposure
than endocrine-sensitive endpoints in ﬁsh.3.4.3. Other scientiﬁc literature
Two potentially relevant studies were identiﬁed in the litera-
ture search pertaining to male reproductive toxicity in ﬁsh (Sup-
plemental Table S2). However, both studies were evaluated as
‘‘Category 3 – Unreliable’’ using the ToxRTool system due to meth-
odological issues including inadequate identiﬁcation of the test
material, no analytical conﬁrmation of exposure concentrations,
and failure to identify the sex of the ﬁsh used in blood steroid anal-
ysis. One study that assessed gonadal function in frogs was deemed
‘‘Category 3 – Unreliable’’ owing to high control mortality and
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subjects.
3.4.4. In vivo pesticide registration studies
Aside from published studies, there are numerous repeat-dose
studies that have been conducted as part of the pesticide registra-
tion program. These studies provide an assessment of numerous
potential toxicological endpoints of interest, including endocrine
function. Thus, there is existing data that should be considered as
part of the WoE in addition to the Tier 1 battery. Many of these
studies are considered OECD level four studies as they assess po-
tential adverse effects in an apical manner (i.e., multiple
pathways).
Speciﬁc studies that meet EPA guidelines and which are most
relevant for the evaluation of potential interaction with the endo-
crine system are developmental toxicity studies in mice, rats and
rabbits, 13-week repeat-dose toxicity studies in rats, a two-
generation reproductive toxicity study in rats, a developmental
neurotoxicity (DNT) study in rats, and multiple chronic toxicity/
oncogenicity studies (as reviewed in Eaton et al., 2008; US EPA,
2000b). These studies were conducted in accordance with interna-
tionally accepted test guidelines in place at the time of conduct,
and the more recent studies have been conducted according to
GLP standards. Many of the studies used rats and, therefore, are
considered relevant to the mammalian Tier 1 EDSP data
requirements.
These study designs included variety and multitude of end-
points of toxicological relevance, which speciﬁcally inform on po-
tential endocrine effects following exposure (Table 3).
Furthermore, similar endpoints were evaluated across study de-
signs of differing length and scope; thus, increasing the opportu-
nity to identify endocrine-related effects. In the EDSTAC report to
EPA (EDSTAC, 1998), speciﬁc reference was made to the mamma-
lian two-generation reproductive toxicity study. According to the
EPA:
‘‘. . . potential hormonal effects can be detected through behavioral
changes, ability to become pregnant, duration of gestation, signs of
difﬁcult or prolonged parturition, apparent sex ratio (as ascer-
tained by anogenital distances) of the offspring, feminization or
masculinization of offspring, number of pups, stillbirths, gross
pathology and histopathology of the vagina, uterus, ovaries, testis,
epididymis, seminal vesicles, prostate, and any other identiﬁed tar-
get organs’’In the chlorpyrifos two-generation reproductive toxicity study
(Breslin et al., 1996), there is no evidence of female reproductive
toxicity or effects on female reproductive tissue structure or func-
tion, including no genetic damage to the ovum, no alterations in
ovulation or estrous cycle, no alterations in endocrine function
and no complications during pregnancy. Additionally, long-term
studies in both rats and mice revealed no adverse treatment-re-
lated effects on reproductive organ weights or neoplastic or non-
neoplastic histopathological changes in reproductive tissues.
Similarly, there is no evidence of male reproductive toxicity or
effects on reproductive tissue structure or function in the two-gen-
eration reproduction study in rats (Breslin et al., 1996), including
no genetic damage to the spermatozoon or its precursor, no
impairment in sperm or seminal ﬂuid production or reproductive
performance, and no alterations in endocrine function. Long-term
studies in both male rats and mice revealed no adverse treat-
ment-related effects on reproductive organ weights and neoplastic
or non-neoplastic histopathological lesions in reproductive tissues.
The two-generation reproduction and developmental toxicity
studies for chlorpyrifos demonstrate that even at doses thousands
of times greater than estimated human exposure levels, chlorpyri-fos has no effect on male or female fertility, litter size or viability,
or the number of embryos implanted in the uterus (Breslin et al.,
1996; US EPA, 2000b; Eaton et al., 2008). Collectively, the studies
conducted as part of the FIFRA required testing for registered pes-
ticides have assessed a wide range of biological effects related to
endocrine function, and no endocrine effects have been found in
experimental animals that have been exposed from conception
through adulthood or adulthood to old age. Recently, the California
Ofﬁce of Environmental Health Hazard Assessment’s (OEHHA)
Developmental and Reproductive Toxicant Identiﬁcation Commit-
tee (DART) declined to list chlorpyrifos as a reproductive (male
or female) or developmental toxicant under California Proposition
65 (OEHHA, 2008) as it did not meet the listing criteria.
Taken together, there were no consistent patterns of treatment-
related changes in reproductive system development, reproductive
organ weights, thyroid weight, or histopathology of the reproduc-
tive organs, accessory sex tissues (prostate, seminal vesicles, pre-
putial gland), pituitary, or thyroid. The two-generation study was
conducted in 1991, before the revision of the test guideline in
1998, which makes this study ineligible to be a Level 5 study; still,
there were no treatment-related changes in reproductive parame-
ters (e.g., time to mating, fertility/reproductive indices, litter size,
etc.) in the two-generation study. Puberty onset was not affected
by chlorpyrifos treatment in the DNT study. Therefore, previous
toxicity studies with chlorpyrifos do not support a primary effect
on the estrogen, androgen or thyroid pathways.3.5. Level 5
3.5.1. Fish full life cycle test
A FIFRA 72-5 guideline compliant GLP study in the fathead min-
now (P. promelas) was previously conducted (Mayes et al., 1993).
Chlorpyrifos (control, solvent control, 0.083, 0.144, 0.3, 0.568 and
1.093 lg/L) was administered in a ﬂow-through exposure system
starting from eggs through to adults that laid eggs and ﬁnally
through to 32 day juveniles of the F1 generation. Mayes et al. con-
cluded, ‘‘Evaluation of the results of this study indicate that mor-
tality was the most consistently sensitive toxicity endpoint.
Larvae less than 25 days of age were the most susceptible life stage.
Statistically signiﬁcant effects on growth were transient and non-
systematic in nature; statistically signiﬁcant effects on reproduc-
tive end-points were not observed.’’ The reproductive endpoints
measured were number of spawns, mean spawns per breeding
unit, average number of eggs laid, mean number of eggs laid per
spawning unit, mean percent hatch and days to ﬁnal hatch. There
were no observations on secondary sex characteristics or repro-
ductive behaviors, and no measurements of reproductive biomark-
ers such as plasma VTG, plasma sex steroid concentrations,
gonado-somatic index or gonad histopathology, and the FIFRA
72-5 study guideline only utilized two true replicate tanks within
which four (pseudo-replicate) spawning units were constructed.
Thus, Mayes et al. stated, ‘‘As expected, the reproductive data were
variable’’ perhaps due to the low level of true replication in this
test method. However, there was no indication of any trend toward
a treatment-related dose-responsive effect on average number of
eggs laid or mean number of eggs laid per spawning unit in this
study. The lowest observed effect concentration was 1.093 lg/L
based on effects on survival of larvae, leading to a reported no ob-
served effect concentration of 0.568 lg/L. There were no measure-
ments of inhibition of ChE activity by chlorpyrifos in this study.4. Discussion
When evaluating Tier 1 data, in vivo assays, coupled with
in vitro assays, provide data for the WoE to determine whether
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to Tier 2 testing. The results of in vitro assays may facilitate inter-
pretation of positive or negative in vivo assays to allow an accurate
determination of endocrine potential. For example, an antiestrogen
operating via estrogen receptor binding could produce positive re-
sults in the estrogen receptor binding assay, uterotrophic assay, the
pubertal female assay, and the ﬁsh short-term reproduction assay,
whereas an antiestrogenic response mediated via altered aroma-
tase activity may generate positive results in the steroidogenesis
assay, aromatase assay, the pubertal female assay, and the ﬁsh
short-term reproduction assay. In these cases, the proﬁle of re-
sponses across EDSP assays would offer assurance that the battery
did not produce false positive results and that assays that rely on
apical endpoints (e.g., the pubertal female assay) were positive
due to an endocrine mode-of-action.
Within the context of the current EDSP Tier 1 battery, results of
in vitro assays alone would not generally be expected to provide a
sufﬁcient basis to support the need for Tier 2 testing. When weigh-
ing the different lines of evidence and examining the balance of po-
sitive and negative results, EPA expects that in vivo evidence would
typically be given greater overall inﬂuence in the WoE evaluation
than in vitro ﬁndings because of the inherent limitations of such as-
says, which include the inability to account for absorption, distri-
bution, metabolism, and excretion of the compound, as well as
normal intact physiological conditions (e.g., the ability of an animal
to compensate for endocrine alterations). The relative sensitivity
and speciﬁcity of the measured endpoints also would be relevant
considerations.
For chlorpyrifos, all eleven assays included under the EDSP Tier
1 Screening Program have recently been conducted to evaluate po-
tential effects on the estrogen, androgen and thyroid signaling
pathways. To put these data into context, ChE inhibition was eval-
uated concurrently in most of the in vivo EDSP assays with the
exception of the uterotrophic assay, where ChE activity could be
extrapolated from a previously conducted study (Marty et al.,
2012). ChE inhibition serves as a sensitive endpoint for chlorpyrifos
exposure and/or systemic toxicity.
4.1. WoE – the estrogen pathway
In following the guidance prescribed by EPA on WoE for EDSP
ﬁndings, the hypothesis for potential effects on the estrogen path-
ways was as follows: Based upon WoE evaluation of EDSP Tier 1
data and OSRI, chlorpyrifos does not demonstrate potential to
interact with the estrogen pathway.
Table 5 summarizes the results of the chlorpyrifos EDSP studies
and endpoints relevant for determining potential to interact with
the estrogen pathway. Various modes-of-action that may lead to
altered estrogen signaling are delineated to facilitate determina-
tion of the potential for estrogenic, antiestrgenic, steroidogenesis
or hypothalamic–pituitary–gonadal (HPG) axis effects. Phrases in-
cluded in the table are derived from the conclusions of the individ-
ual EDSP reports as summarized in this report. Where a response is
not provided (i.e., NA), that particular mode-of-action is not rele-
vant to the Tier 1 EDSP assay being assessed (e.g., HPG axis is not
assessed in the ER binding assay).
In reviewing results for evaluation of estrogenic/antiestrgenic
activity from Tier 1 screening results, there was a weak response
in the ERTA assay at 105–104 M chlorpyrifos, which could poten-
tially indicate estrogen agonism. Furthermore, in the steroidogen-
esis assay, estradiol levels were increased at these same
concentrations (105–104 M) of chlorpyrifos, which could suggest
increased levels of estradiol available to produce an estrogenic re-
sponse. However, there is no evidence of estrogenicity across the
body of in vivo data, which argues against the relevance of these
in vitro ﬁndings. Numerous estrogen-sensitive endpoints were neg-ative (i.e., no treatment-related changes) in both the in vivo Tier 1
assays and previous toxicity studies, including:
 Uterotrophic assay: Chlorpyrifos did not induce uterine weight
increases. This assay provides a consistent and highly sensitive
indicator of estrogenic activity (e.g., Kanno et al., 2003). The
results of the chlorpyrifos uterotrophic assay were supported
by a negative ER binding assay using rat uterine cytosols, which
provides additional evidence that chlorpyrifos does not interact
directly with ERalpha.
 Female pubertal assay: Chlorpyrifos had no effect on age or
body weight at vaginal opening, estrous cyclicity (length, pat-
tern or age at ﬁrst estrus), pituitary, ovarian and uterine (wet
or blotted) weights and uterine and ovarian histopathology.
One of the strengths of the pubertal assays is that these assays
examine endocrine endpoints in young animals during a
dynamic period when integrated function of the endocrine sys-
tem is needed; thus, the available data indicate that the female
pubertal assay is relatively sensitive to alterations in estrogen
function. During validation, the female pubertal assay was
shown to detect numerous estrogenic compounds including
ethynyl estradiol, methoxychlor, and tamoxifen (mixed ago-
nist/antagonist) (US EPA, 2007b). The proﬁle of effects for estro-
gen agonists included early vaginal opening, reduced body
weight at vaginal opening, early ﬁrst estrus, altered estrous
cyclicity (possible persistent estrus), decreased ovarian weight,
increased uterine weight, and altered ovarian/uterine histology.
Chlorpyrifos does not exhibit an estrogenic proﬁle on the basis
of these endpoints.
 Fish short-term reproduction assay: Chlorpyrifos had no effect
on estrogen-sensitive endpoints, including vitellogenin levels,
gonado-somatic indices, ovarian/testicular histopathology,
tubercle scores, or plasma sex steroid levels. During validation,
the ﬁsh short-term reproduction assay was shown to detect
both strong and weak acting estrogenic compounds including
estradiol, ethynyl estradiol, methoxychlor, and nonylphenol
(US EPA, 2007c). The proﬁle of effects for estrogen agonists
included increased vitellogenin levels (particularly in males),
decreased gonado-somatic indices (males and females),
decreased male tubercle score, altered sex steroid concentra-
tions, and altered ovarian and testicular histology. Chlorpyrifos
does not exhibit an estrogenic proﬁle on the basis of these
endpoints.
 Results of previous reproductive toxicity studies (reviewed in
US EPA (2000b) and Breslin et al. (1996)) also support a lack
of effects on estrogen-sensitive endpoints. There were no expo-
sure-related effects on reproductive indices, including mating,
fertility, conception, time to mating, gestation length, and ges-
tation survival index. There were no signs of dystocia in chlor-
pyrifos-exposed dams in either generation. Chlorpyrifos did
not alter reproductive organ histopathology, including the pitu-
itary, ovaries, oviducts, uterus, vagina and cervix. Thus, there
was no pattern of altered estrogenicity in female rats treated
with chlorpyrifos. Overall, the data do not support any chlor-
pyrifos-mediated estrogenic effects even at doses that exceed
the thresholds for red blood cell and brain ChE inhibition.
There was a weakly positive response in the ERTA assay with
chlorpyrifos. The ERTA reportedly has good concordance with
in vitro ER binding and in vivo uterotrophic responses for active
parent compounds (Takeyoshi, 2006); however, this was not ob-
served in the Tier 1 battery with chlorpyrifos. The test guideline
criteria for a positive response in the ERTA is based on reaching
or exceeding a PC10, which is 10% of the positive control response
at 1 nM 17b-estradiol, and this relatively low criteria for a positive
assay may result in numerous false-positive results and jeopardize
Table 5
Summary of estrogenic pathway responses in the EDSP studies.
Estrogenicity Antiestrgenicity Altered steroidogenesis Altered hypothalamic–
pituitary–gonadal axis
OECD CF
level
In vitro assays
ER binding assay Negative/not interactive Negative/not interactive NA NA Level 2
ER transactivation
assay
Weak response at 105 and
104 Ma
NA NA NA
Steroidogenesis assay NA NA ;T, "E2 at 10 and 100 lMa NA
Aromatase assay NA NA Non-inhibitor NA
In vivo assays
Uterotrophic assay Negative/non-estrogenic NA NA NA Level 3
Female pubertal assay Negative/ no evidence of
endocrine activity
Negative/ no evidence of
endocrine activity
Negative/ no evidence of
endocrine activity
Negative/ no evidence of
endocrine activity
Level 4
Fish short-term
reproduction assay
No estrogenic effects No antiestrgenic effects No steroidogenesis effects No HPG axis effects
NA – not directly applicable to the speciﬁc pathway under evaluation.
a Effect observed at in vitro concentrations that correspond to in vivo plasma levels with a high level of plasma, RBC and brain cholinesterase inhibition.
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confound the results of transactivation assays, including com-
pound-mediated inhibition of histone deacetylase or luciferase
(i.e., luciferase inhibitors often result in reporter stabilization
and increased signal), chemical interaction with ﬂuorophores,
membrane perturbations, stress-inducing compounds, apopoto-
sis/cytotoxicity, etc.) (Hassig et al., 1998; Auld et al., 2008; Thorne
et al., 2012). For the steroidogenesis assay, the decrease in
hormone levels may be related to initial phases of cellular toxicity.
Decreases in testosterone and increases in estradiol could be re-
lated to stress-related differences in cell metabolism, such that
cells are synthesizing less testosterone and pre-existing levels of
estradiol present in the assay medium (Nu-Serum) were not
metabolized as quickly at high concentrations of chlorpyrifos. In
addition, alterations in testosterone and estradiol levels in the ste-
roidogenesis assay only occurred at high concentrations in vitro,
which would be associated with signiﬁcant inhibition of RBC and
brain ChE in in vivo studies. Moving into higher Tier studies that
more robustly inform on the relative signiﬁcance of these Level 2
responses, it is clear from the uterotrophic and female pubertal as-
say that there is no indication of estrogenicity, antiestrogenicity,
altered steroidogenesis, or altered HPG axis function following
treatment with chlorpyrifos, even at concentrations which are
associated with signiﬁcant inhibition of brain ChE. In the ﬁsh
short-term reproduction assay, the reduction in fecundity was clo-
sely correlated with reductions in brain ChE activity, a sign of sys-
temic toxicity. Therefore, the experimental evidence from the ﬁsh
short-term reproduction assay indicates that chlorpyrifos does not
interact with the estrogen pathway in ﬁsh.
A review of the guideline studies discussed earlier, which have
been used for regulatory requirements for registration, revealed no
indication from a diverse set of biological markers (e.g., organ
weights, growth parameters, sexual maturation, reproductive indi-
ces, histopathology of estrogen-sensitive organs) that chlorpyrifos
perturbs estrogenic endpoints or pathways in mammalian species.
Thus, previous data support the conclusions of the Tier 1 assays.
4.2. WoE – the androgen pathway
The hypothesis for the androgen pathway is as follows: based
upon WoE evaluation of EDSP Tier 1 data and OSRI, chlorpyrifos
did not demonstrate potential to interact with the androgen
pathway.
Table 6 below summarizes the results of the chlorpyrifos
EDSP studies and endpoints relevant for determining potential tointeract with the androgen pathway. Various modes-of-action that
may lead to altered androgen signaling are delineated to facilitate
determination of the potential for androgenic, antiandrogenic, ste-
roidogenesis or hypothalamic–pituitary–gonadal (HPG) axis ef-
fects. Phrases included in the table are derived from the
conclusions of the individual EDSP reports as summarized in this
report. Where a response is not provided (i.e., NA), that particular
portion of the pathway is not relevant to the Tier 1 EDSP assay
being assessed (e.g., HPG axis is not assessed in the AR binding
assay).
In reviewing results for evaluation of androgenic/antiandrogen-
ic activity from Tier 1 screening results, there was a weak response
in the AR binding assay at 104–103 M chlorpyrifos, which could
potentially indicate androgen agonism or antagonism. Further-
more, in the steroidogenesis assay, testosterone levels were de-
creased at high concentrations (105–104 M) of chlorpyrifos,
which could suggest decreased levels of testosterone available to
produce an androgenic response. However, there is no evidence
of androgenicity/antiandrogenicity across the body of in vivo data,
which argues against the relevance of these in vitro ﬁndings.
Numerous androgen-sensitive endpoints were negative (i.e., no
treatment-related changes) in both the in vivo Tier 1 assays and
previous toxicity studies, including:
 Hershberger assay: Chlorpyrifos did not induce signiﬁcant
increases in two AST weights in the androgenic portion of the
assay nor were there signiﬁcant decreases in two AST weights
in the antiandrogenic portion of the assay. The Hershberger
assay is speciﬁcally designed to detect compounds that interact
at the androgen receptor or inhibit 5alpha-reductase; therefore,
a signiﬁcant interaction with the androgen receptor was not
supported. This assay provides a consistent and highly sensitive
indicator of both androgenic and antiandrogenic activity. Both
androgenic compounds (e.g., methyltestosterone and trenbo-
lone) and antiandrogenic compounds (e.g., procymidone, vinc-
lozolin, linuron, p,p0-DDE) were positively identiﬁed during
Hershberger validation (e.g., Kennel et al., 2004; Yamasaki
et al., 2006; Owens et al., 2007).
 Male pubertal assay: Chlorpyrifos had no effect on age or body
weight at preputial separation, and no effects on weights of the
testes, epididymides, ventral prostate, dorsolateral prostate,
seminal vesicles plus coagulating glands (with and without
ﬂuid), levator ani-bulbocavernosus muscles and pituitary.
Serum testosterone levels and testicular and epididymal histo-
pathology were unaffected in chlorpyrifos-treated animals.
Table 7
Summary of thyroid pathway responses in the EDSP studies.
Altered hypothalamic–
pituitary–thyroid axis
OECD conceptual
framework level
In vivo assays
Amphibian
metamorphosis
assay
Negative/no evidence of
thyroid activity
No HPT axis effects
Level 3
Male pubertal assay Negative/no evidence of
thyroid activity
Level 4
Female pubertal
assay
Negative/no evidence of
thyroid activity
Table 6
Summary of androgenic pathway responses in the EDSP studies.
Androgenicity Antiandrogenicity Altered steroidogenesis Altered Hypothalamic–
pituitary–gonadal axis
OECD CF
level
In Vitro assays
AR binding assay Equivocal response at 104
and 103 M
Equivocal response at 104
and 103 M
NA NA Level 2
Steroidogenesis assay NA NA ;T, "E2 at 10 and 100 lMa NA
In vivo assays
Hershberger assay Negative for androgenic
activity
Negative for antiandrogenic
activity
Negative/no evidence NA Level 3
Male pubertal assay Negative/no evidence of
endocrine activity
Negative/no evidence of
endocrine activity
Negative/no evidence of
endocrine activity
Negative/no evidence of
endocrine activity
Level 4
Fish short-term
reproduction assay
No androgenic effects No antiandrogenic effects No steroidogenesis effects No HPG axis effects
NA – not directly applicable to the speciﬁc pathway under evaluation.
a Effect observed at in vitro concentrations that correspond to in vivo plasma levels with a high level of plasma, RBC and brain cholinesterase inhibition.
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examine endocrine endpoints in young animals during a
dynamic period when integrated function of the endocrine sys-
tem is needed; thus, the available data indicate that the male
pubertal assay is relatively sensitive to alterations in androgen
status. In pre-validation work, the androgen agonist, methyltes-
tosterone, decreased the age at puberty onset, increased the
weight of accessory sex tissues (ventral prostate and seminal
vesicles) and decreased the weight of reproductive tissues (tes-
tes and epididymides) in the male pubertal assay (US EPA,
2007d). This assay also was shown to detect numerous antian-
drogenic compounds, including ﬂutamide, vinclozolin, linuron,
and methoxychlor (mixed estrogenic effects and antiandrogenic
effects) (US EPA, 2007d). The general proﬁle of effects for andro-
gen antagonists included delayed preputial separation,
decreased organ weights (i.e., ventral prostate, seminal vesicle,
levator ani-bulbocavernosus and epididymides), altered serum
testosterone levels, and altered testicular and epididymal his-
tology. Chlorpyrifos does not ﬁt the proﬁle of an androgenic
or antiandrogenic compound.
 Fish short-term reproduction assay: Chlorpyrifos had no effect
on vitellogenin levels, gonado-somatic indices, ovarian/testicu-
lar histopathology, tubercle scores, or plasma sex steroid levels.
During validation, the ﬁsh short-term reproduction assay was
shown to sensitively detect androgenic compounds, including
17b-trenbolone and methyl testosterone, and antiandrogenic
compounds, including ﬂutamide, p,p0-DDE, and vinclozolin (US
EPA, 2007c). The proﬁle of effects for androgen agonists
included altered vitellogenin levels (males and females), altered
gonado-somatic index (males and females), increased tubercle
score (males and females), altered sex steroid concentrations
(males and females), and altered ovarian and testicular histol-
ogy. The proﬁle of effects for antiandrogens included increased
vitellogenin levels (males and females), altered gonado-somatic
indices (males and females), decreased male tubercle score, and
altered ovarian and testicular histology. Chlorpyrifos does not
ﬁt the proﬁle of either an androgenic or antiandrogenic
compound.
 Results of three previous reproductive toxicity studies (Breslin
et al., 1996; Dietz et al., 1983; Thompson et al., 1971) also sup-
port a lack of effects on androgen-sensitive endpoints. There
were no exposure-related effects on reproductive indices,
including mating, fertility, conception, time to mating, gestation
length, and gestation survival index. There was no evidence of
hypospadias or ectopic testes. Chlorpyrifos did not alter repro-
ductive organ histopathology, including the pituitary, testes,
epididymides, prostate, and seminal vesicles with coagulating
glands. Thus, there was no pattern of altered antiandrogenicity
in male rats treated with chlorpyrifos. Overall, the data do notsupport any chlorpyrifos-mediated androgenic or antiandro-
genic effects even at doses that exceed the thresholds for red
blood cell and brain ChE inhibition.
The equivocal response in the AR binding assay and alterations
in testosterone and estradiol levels in the steroidogenesis assay
only occurred at high concentrations in vitro, which would be asso-
ciated with signiﬁcant inhibition of RBC and brain ChE in in vivo
studies. Moving into higher tier studies that more robustly inform
on the relative signiﬁcance of these Level 2 responses, it is clear
from the Hershberger assay and the male pubertal assay that there
is no indication of androgenicity, antiandrogenicity, altered steroi-
dogenesis, or altered HPG axis function following treatment with
chlorpyrifos, even at concentrations which are associated with sig-
niﬁcant inhibition of brain ChE. In the ﬁsh short-term reproduction
assay, despite the signiﬁcant effects of chlorpyrifos on fecundity,
therewere no changes in androgen-related endpoints such as testes
histopathology, plasma testosterone, or male secondary sex charac-
teristics. The reduction in fecundity was closely correlated with
reductions in brain ChE activity. Therefore, the experimental evi-
dence from the ﬁsh short-term reproduction assay indicates that
chlorpyrifos does not interact with the androgen pathway in ﬁsh.
A review of the guideline studies discussed earlier, which have
been used for regulatory requirements for registration, revealed no
indication from a diverse set of biological markers (e.g., organ
weights, growth parameters, sexual maturation, reproductive indi-
ces, histopathology of estrogen-sensitive organs) that chlorpyrifos
perturbs androgenic endpoints or pathways in mammalian species.
Thus, previous data support the conclusions of the Tier 1 assays.
4.3. WoE – the thyroid pathway
The hypothesis for the thyroid pathway is as follows: based
upon WoE evaluation of EDSP Tier 1 data and OSRI, chlorpyrifos
does not demonstrate potential to interact with the thyroid
pathway.
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and endpoints relevant for determining potential to interact with
the hypothalamic-pituitary-thyroid axis pathway. Phrases in-
cluded in the table are derived from the conclusions of the individ-
ual EDSP reports as summarized in this report.
There are no Level 2 data available to evaluate aspects of thy-
roid function. Across Level 3 (amphibian metamorphosis assay)
and Level 4 (male, female pubertal assays) data, there was no indi-
cation that the thyroid pathway represents a target organ for chlor-
pyrifos, even at dose levels which are associated with signiﬁcant
inhibition of red blood cell and brain ChE, the most sensitive mark-
ers of chlorpyrifos exposure and toxicity, respectively. ChE is a
known biological target that is consistent with the mechanism of
action for chlorpyrifos and other OP compounds. Numerous thy-
roid-sensitive endpoints were negative (i.e., no treatment-related
changes) in both the in vivo Tier 1 assays and previous toxicity
studies, as below.
 AMA: Chlorpyrifos reduced snout-vent length, wet weight,
developmental stage and normalized hind limb length at the
highest concentration, but decreases in these endpoints (relative
to controls) are not speciﬁc for a thyroid-relatedmode-of-action
(OECD, 2007). Signs of advanced development (advanced devel-
opmental stage and increased hind limb length relative to con-
trols), asynchronous development and altered thyroid
histopathology are responses that are more speciﬁc for thyroid-
related effects (OECD, 2007). With chlorpyrifos, there were no
treatment-relatedhistopathological changes in the thyroid gland
and no signs of advanced or asynchronous development, which
suggests that thedelayeddevelopmental effectswerenot thyroid
mediated. In the validation of the AMA, inhibitors of thyroid hor-
mone synthesis (i.e., propylthiouracil, methimazole, sodiumper-
chlorate, benzophenone-2) produced signiﬁcant developmental
delays coupled with altered thyroid histopathology. Develop-
mental delaywithout an accompanying alteration in thyroid his-
topathology is likely not thyroid mediated for two reasons: (1)
developmental delay in tadpoles is common in response togener-
alized stress and delayed tadpole growth (Wilbur and Collins,
1973; OECD, 2007) and (2) altered thyroid histopathology in
response to inhibitorsof thyroidhormonesynthesis is a relatively
sensitive endpoint for this mode-of-action; thus, absence of a
response in this endpoint is agood indication thatdelays indevel-
opment are not speciﬁc to alterations in the thyroid pathway
(Coady et al., 2010;Grimet al., 2009; Pickford, 2010). Thus, chlor-
pyrifos does not ﬁt the proﬁle of a thyroid-active compound. ChE
activitywasdecreased inboth the tail andhind limbtissueatboth
the intermediate and highest concentration, which again sup-
ports the conclusion that ChE inhibition is a sensitive endpoint
for chlorpyrifos exposure/toxicity.
 Male and female pubertal assays: Chlorpyrifos had no effect on
serum T4 or TSH levels, thyroid weights or thyroid histopathol-
ogy. During validation, the male and female pubertal assays
were shown to detect numerous thyroid active compounds,
including propylthiouracil, DE-71, ammonium perchlorate
(tested in males only), and phenobarbital (thyroid effects in
females only) (US EPA, 2007b,d). The general proﬁle of effects
for thyroid-active compounds included decreased T4, increased
TSH, increased thyroid weight and/or altered thyroid histopa-
thology (follicular cell hypertrophy/hyperplasia with decreased
amounts of colloid). Chlorpyrifos does not ﬁt the proﬁle of a thy-
roid-active compound.
 A review of the guideline studies used for regulatory require-
ments for registration revealed no evidence (e.g., no effects on
thyroid weights, growth parameters, or thyroid histopathology)
that chlorpyrifos perturbs thyroid endpoints or pathways in
mammalian species.4.4. Relative sensitivity of endocrine endpoints (E,A,T) vs ChE
inhibition
To put these data into context, ChE inhibition was evaluated in
the relevant in vivo EDSP assays with the exception of the utero-
trophic assay, where ChE inhibition was extrapolated from a previ-
ous study (Marty et al., 2012). From these data, it is clear that ChE
inhibition remains the most sensitive marker of exposure to chlor-
pyrifos. In the in vitro assays in which equivocal or slightly positive
effects were reported, it is noteworthy that the concentrations
associated with these responses (e.g., 10–100 lM) would be asso-
ciated with signiﬁcant RBC and brain ChE inhibition in mammals if
equivalent in vivo levels were achieved. Additionally, pharmacody-
namic modeling of chlorpyrifos in mammals has demonstrated
that signiﬁcant RBC ChE inhibition occurs at levels of 1 lM, which
is well below the threshold for effects reported in any Tier 1 mam-
malian screening assay, conﬁrming that ChE inhibition remains a
more sensitive marker of chlorpyrifos toxicity than any endpoint
included in the Tier 1 mammalian screening assays. In the current
regulatory scenario, chlorpyrifos exposures are designed to prevent
RBC ChE inhibition; therefore, by preventing this effect, protection
against potential endocrine-mediated effects also is insured.
ChE inhibition accounts for the effects seen in some of the EDSP
Tier 1 assays. Regarding the relationship between ChE inhibition
and the responses observed in the ﬁsh short-term reproduction as-
say, there is a high degree of correlation between brain ChE activity
and fecundity in the ﬁsh short-term reproduction assay. Linear
regression of these two response variables resulted in coefﬁcient
of determination values of R2 = 0.875 and R2 = 0.908 for male and
female brain ChE, respectively. These results are in general agree-
ment with the ﬁndings of Jarvinen et al. (1983) in which it was re-
ported that a reduction to 50% of control brain ChE was associated
with signiﬁcant reductions in fathead minnow reproductive per-
formance. Similarly, in the amphibian metamorphosis assay,
reductions in measures of growth (wet weight and snout-vent
length) were highly correlated with inhibition of ChE activity in tail
muscle tissues. Linear regression of these responses resulted in
coefﬁcient of determination values of R2 = 0.938 and R2 = 0.960
for wet weight and snout-vent length, respectively. These high de-
grees of correlation suggest a direct relationship exists between
ChE inhibition and the effects observed in the ﬁsh and frog assays.
The underlying physiological mechanisms linking ChE inhibition
with these effects remains to be elucidated. However, it may be
concluded based on the WoE of the studies performed in the EDSP
(and considering published literature and existing GLP studies)
that such physiological mechanisms do not include direct interac-
tion with the estrogen, androgen or thyroid hormone systems.5. Conclusion
The conclusion of the WoE evaluation is that chlorpyrifos dem-
onstrates no potential to interact with the endocrine system,
including estrogen, androgen, or thyroid pathways. This conclusion
is supported by results from Tier 1 screening which failed to iden-
tify either a sentinel endocrine target or pathway, particularly at
the higher levels of Tier 1 screening with dose levels that caused
signiﬁcant ChE inhibition. Numerous guideline studies have been
conducted for registration purposes and have not identiﬁed the
endocrine system as a primary toxicological target. The WoE con-
clusion that chlorpyrifos does not interact with the endocrine sys-
tem is bolstered by the assessment of potential endocrine activity
across many biological levels of organization, across receptor types
(mammalian and ecological), and through incorporation of test
concentrations and doses which consistently produced signiﬁcant
262 D.R. Juberg et al. / Regulatory Toxicology and Pharmacology 66 (2013) 249–263ChE inhibition (the most sensitive marker of exposure and the
mechanism of action for chlorpyrifos).
Based on the WoE of current Tier 1 screening results, coupled
with available knowledge of chlorpyrifos and its mechanism of ac-
tion and toxicological proﬁle, there is no rationale or scientiﬁc ba-
sis for pursuing further endocrine evaluation of this molecule.
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